---
schema_version: "secwatch.filing_event.v1"
accession: "0001232524-26-000012"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:41:22.024655+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Jazz Pharma FY2025 revenue $4.3B (+5% YoY); GAAP net loss $356M vs $560M income in 2024

## Summary
- Total revenues record $4.3B in FY2025 (+5% YoY); Q4 revenue $1.2B (+10% YoY).
- GAAP net loss $356M ($5.84 diluted loss per share) vs prior year income of $560M ($8.65 EPS).
- Non-GAAP adjusted net income $522M ($8.38 EPS) vs $1.35B ($20.65 EPS) in 2024; adjusted down significantly.
- Xywav $1.7B (+12%), Epidiolex $1.1B (+9%) in 2025; Modeyso launch generated $48M.
- 2026 revenue guidance $4.25-$4.50B; sBLA submission for zanidatamab in GEA expected in 1Q26.

## SEC filing metadata
- accession: 0001232524-26-000012
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000123252426000012/0001232524-26-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000123252426000012/jazz-20260224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001232524-26-000012
- JSON: https://secwatch.observer/filing/0001232524-26-000012.json
- Plain text: https://secwatch.observer/filing/0001232524-26-000012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.